Alessandra Lopes
Overview
Explore the profile of Alessandra Lopes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
518
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bausart M, Vanvarenberg K, Ucakar B, Lopes A, Vandermeulen G, Malfanti A, et al.
Pharmaceutics
. 2022 May;
14(5).
PMID: 35631612
Combination immunotherapy has emerged as a promising strategy to increase the immune response in glioblastoma (GBM) and overcome the complex immunosuppression occurring in its microenvironment. In this study, we hypothesized...
2.
Feola S, Russo S, Martins B, Lopes A, Vandermeulen G, Fluhler V, et al.
Front Immunol
. 2022 May;
13:826164.
PMID: 35493448
Oncolytic Viruses (OVs) work through two main mechanisms of action: the direct lysis of the virus-infected cancer cells and the release of tumor antigens as a result of the viral...
3.
Fourniols T, Maggio V, Rafael D, Colaco A, Vidal E, Lopes A, et al.
Eur J Pharm Biopharm
. 2022 Jan;
171:39-49.
PMID: 34998911
Bromodomain and extraterminal domain protein inhibitors (BETi) for cancer treatment did not convince during their first clinical trials. Their epigenetic mechanism of action is still not well understood, even if...
4.
Lopes A, Bastiancich C, Bausart M, Ligot S, Lambricht L, Vanvarenberg K, et al.
J Immunother Cancer
. 2021 Apr;
9(4).
PMID: 33795383
Background: Strategies to increase nucleic acid vaccine immunogenicity are needed to move towards clinical applications in oncology. In this study, we designed a new generation of DNA vaccines, encoding an...
5.
Tsakiris N, Papavasileiou M, Bozzato E, Lopes A, Vigneron A, Preat V
Int J Pharm
. 2019 Aug;
569:118588.
PMID: 31377406
The purpose of this study was to investigate the feasibility of an intravenously administered combinational therapy using lipid nanocapsules (LNCs) as a drug delivery carrier for the treatment of different...
6.
Lopes A, Feola S, Ligot S, Fusciello M, Vandermeulen G, Preat V, et al.
J Immunother Cancer
. 2019 Jul;
7(1):174.
PMID: 31291991
Background: DNA vaccines against cancer held great promises due to the generation of a specific and long-lasting immune response. However, when used as a single therapy, they are not able...
7.
Kos S, Lopes A, Preat V, Cemazar M, Tratar U, Ucakar B, et al.
PLoS One
. 2019 Jun;
14(5):e0217762.
PMID: 31150505
We aimed to explore whether the combination of intradermal DNA vaccination, to boost immune response against melanoma antigens, and immune checkpoint blockade, to alleviate immunosuppression, improves antitumor effectiveness in a...
8.
Lopes A, Vandermeulen G, Preat V
J Exp Clin Cancer Res
. 2019 Apr;
38(1):146.
PMID: 30953535
The recent developments in immuno-oncology have opened an unprecedented avenue for the emergence of vaccine strategies. Therapeutic DNA cancer vaccines are now considered a very promising strategy to activate the...
9.
Lopes A, Vanvarenberg K, Kos S, Lucas S, Colau D, Van den Eynde B, et al.
Sci Rep
. 2018 Oct;
8(1):15732.
PMID: 30356111
DNA vaccination against cancer has become a promising strategy for inducing a specific and long-lasting antitumor immunity. However, DNA vaccines fail to generate potent immune responses when used as a...
10.
Lopes A, Vanvarenberg K, Preat V, Vandermeulen G
Mol Ther Nucleic Acids
. 2017 Sep;
8:404-415.
PMID: 28918040
DNA vaccine can be modified to increase protein production and modulate immune response. To enhance the efficiency of a P815 mastocytoma DNA vaccine, the P1A gene sequence was optimized by...